LGALS2 (Galectin 2)
A beta-galactoside-binding lectin involved in immune modulation and apoptosis
Gene Information Card
| Symbol | LGALS2 |
|---|---|
| Full Name | Galectin 2 |
| Gene Type | Protein coding |
| Chromosomal Location | 22q13.1 |
| NCBI Gene ID | 3957 ncbi.nlm.nih.gov/gene/3957 |
| Ensembl ID | ENSG00000100097 |
| UniProt ID | P05162 |
| OMIM ID | 150571 |
| HGNC ID | 6563 |
| Aliases | HL14, Gal-2 |
Description
LGALS2 (galectin 2) is a member of the galectin family of beta-galactoside-binding proteins. It is involved in modulating cell-cell and cell-matrix interactions, apoptosis, and immune responses. The gene is located on chromosome 22q13.1 and encodes a 14 kDa protein that forms homodimers. LGALS2 is expressed primarily in the gastrointestinal tract, heart, and immune cells, and has been implicated in inflammatory diseases and cancer.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Colorectal cancer | Altered LGALS2 expression may influence tumor cell adhesion and immune evasion; polymorphisms associated with risk | PMID: 19156141 |
| Crohn's disease | LGALS2 polymorphisms (e.g., rs7291467) linked to increased susceptibility via modulation of galectin-2 expression and apoptosis | PMID: 16951684 |
| Myocardial infarction | LGALS2 variants associated with altered inflammatory response and risk of MI | PMID: 17293864 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Colon | 12.3 | Medium |
| Small intestine | 10.1 | Medium |
| Heart | 8.5 | Medium |
| Spleen | 6.2 | Low |
| Lung | 4.8 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| Caco-2 | 15.2 | Colorectal adenocarcinoma cell line |
| HCT 116 | 11.7 | Colorectal carcinoma cell line |
| THP-1 | 9.3 | Monocytic leukemia cell line |
| HeLa | 3.1 | Cervical adenocarcinoma cell line |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| rs7291467 (c.327C>T) | SNP | 0.15 (global) | Intronic variant associated with altered LGALS2 expression and Crohn's disease risk |
| rs10757278 (intergenic) | SNP | 0.25 (global) | Linked to myocardial infarction risk in GWAS |
Mutation functional classification
Loss of Function (LOF)
No confirmed loss-of-function mutations reported in ClinVar or COSMIC.
Gain of Function (GOF)
No confirmed gain-of-function mutations reported.
Dominant Negative (DN)
No dominant-negative mutations described.
View complete mutation data：
Gene Ontology (GO)
| • protein binding (GO:0005515) | • carbohydrate binding (GO:0030246) |
| • apoptotic process (GO:0006915) | • cell adhesion (GO:0007155) |
| • innate immune response (GO:0045087) |
Pathways
• Galectin pathway (Reactome: R-HSA-5621481)
• Apoptosis (KEGG: hsa04210)
Protein Summary
Galectin-2 is a 14 kDa homodimeric protein that binds beta-galactoside residues on glycoproteins. It is secreted via a non-classical pathway and functions extracellularly to modulate cell adhesion, apoptosis, and immune cell activation. Intracellularly, it may participate in pre-mRNA splicing. The protein is highly expressed in the gastrointestinal tract and heart, and its dysregulation is linked to inflammatory bowel disease and colorectal cancer.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| LGALS2 Knockout HEK293 Cell Line | EDJ-KQ5115 | Human | 3957 | Details Get a Quote |
| LGALS2 Knockout HeLa Cell Line | EDJ-KQ53789 | Human | 3957 | Details Get a Quote |
| LGALS2 Knockout A-549 Cell Line | EDJ-KQ62267 | Human | 3957 | Details Get a Quote |
| LGALS2 Knockout HCT 116 Cell Line | EDJ-KQ70751 | Human | 3957 | Details Get a Quote |
